Strides Arcolab, Eli Lilly in pact for cancer drug delivery

Moneycontrol Bureau

Bangalore-based Strides Arcolab and global pharma major Eli Lilly and Co have entered into a strategic partnership to expand delivery of cancer medicines in emerging markets. As a part of the deal, Eli Lilly will in-license a portfolio of high quality, branded generic injectable and oral cancer medicines from Strides arm Agila Specialties. Agila will manufacture the cancer drugs and Eli Lilly will register and market these in multiple geographies across the emerging markets, it said. In addition to the initial ten medicines included as a part of the agreement, Lilly has the right to add additional generic oncology products to the portfolio in the future, Strides added. Strides Arcolab shares hit a 52-week high of Rs 1,224 on NSE on Wednesday. At 14:20 hrs, the stock was trading at Rs 1,183, down 1 percent.